Comprehensive Molecular Testing in Patients With Ovarian Cancer

Video content above is prompted by the following:

Challenges in Comprehensive Molecular Testing

Two primary barriers impact comprehensive molecular testing implementation:

Education:

• Physicians need better awareness about which tests to order, when to order them, and how to interpret results.
• All patients with advanced or recurrent disease should receive comprehensive testing (DNA, RNA, and protein analysis).
• Education must extend to health care providers, patients, and the broader community.

Cost and reimbursement:

• Medicare covers several biomarker tests with little to no patient cost.
• Reimbursement varies by insurance type, with inconsistencies in federal and state funding.
• Improving value requires both better education and more affordable testing options.

Addressing these barriers would support wider adoption of comprehensive molecular testing in ovarian cancer.